Amazon was struggling before mixed second-quarter results, but it has several attractive growth opportunities. Mounting ...

Takeda has shot down candidates acquired in its $525 million Maverick Therapeutics takeover, blowing a hole in its oncology R ...

We recently published a list of The Best and Worst Dow Stocks. In this article, we are going to take a look at where Merck & ...

We can contribute innovation globally,” Xia says. “I think that's very satisfying.” As director general of the World Health ...

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R&D Day in March, Company is on track to initiate Phase 2 ASPEN-Breast and Phase ...

The deal-making activity signals Merck’s determination to stay at the forefront of cancer immunotherapy with new medicines that could complement Keytruda and broaden its portfolio. Janux says ...

Enriqueta Felip, MD, PhD, discusses how results from the phase 3 3475A-D77 trial evaluating subcutaneous pembrolizumab vs ...

The company added to a recent flurry of pledges by pharmaceutical companies, promising $11 billion in new capital and ...

Yelena Y. Janjigian, MD, discusses how to manage the potential adverse events of pembrolizumab when using the recently approved combination of pembrolizumab plus trastuzumab and chemotherapy.

Robert F. Kennedy, Jr. discusses the findings of the Centers for Disease Control and Prevention’s latest Autism and Developmental Disabilities Monitoring Network survey, Washington, D.C., U.S ...

Makers of organoids and cell models cheered the decision and said it will bolster the development of precision medicines, ...